● Recruiting

Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically

Condition: Non-Melanoma Skin Cancer (NMSC) · Benign Skin Growth · Sponsor: Dartmouth-Hitchcock Medical Center

PhaseN/A

Planned participants125

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersYes

About this study

The primary objective of this study is the evaluation of the efficacy of the tissue oxygen imager based on PpIX DF in differentiating benign skin growth from non-melanoma skin cancer (NMSC).

This description comes directly from the study's public registry record.

Talk to the study team

Dylan L Parker, MD · 603-653-2209 · Dylan.J.Parker@Hitchcock.org

Staci Shaw · 603-650-3693 · Staci.L.Shaw@Hitchcock.org

Always discuss trial participation with your own doctor first.

Locations (1)

Dartmouth Hitchcock

Lebanon, New Hampshire, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07201376